Search

Allogene Therapeutics Inc

Lezárt

SzektorEgészségügy

1.67 -2.91

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

1.6600000000000001

Maximum

1.76

Fő mutatók

By Trading Economics

Bevétel

-70K

-43M

Értékesítés

4.6M

4.6M

Egy részvényre jutó nyereség

-0.13

Profit margin

-919.763

Munkavállalók

150

EBITDA

-251K

-40M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+506.51% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-110M

615M

Előző nyitás

4.58

Előző zárás

1.67

Hangulat hírek alapján

By Acuity

50%

50%

134 / 339 Rangsor szerint Healthcare

Allogene Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 16. 23:01 UTC

Allogene Therapeutics Inc is moving higher in after-market hours, reflecting broader market trends following a 1.2% increase in U.S. retail sales for August.

2026. szept. 10. 20:07 UTC

Macro Event

Allogene Therapeutics Inc. shares are higher Thursday, following a cumulative gain since Wednesday's close, despite remaining below its 20-day moving average.

2026. szept. 9. 23:01 UTC

Allogene Therapeutics Inc shares are higher in after-market trading, reversing a three-session decline, though still below the 20-day moving average.

2026. szept. 8. 20:07 UTC

Allogene Therapeutics Inc shares are lower today amid broader market weakness, continuing a decline since Friday's close. No specific company news was identified.

2026. szept. 3. 19:36 UTC

Allogene Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains near the midpoint of its one-month trading range.

2026. aug. 31. 19:16 UTC

News

Allogene Therapeutics Inc shares are lower amid broader market declines following hawkish Fed comments. The company noted progress with cema-cel and FDA designations.

2026. aug. 28. 23:36 UTC

Allogene Therapeutics Inc shares are higher in after-market trading. No specific news was identified to explain this movement.

2026. aug. 27. 23:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock has gained over the past month.

2026. aug. 26. 19:56 UTC

Allogene Therapeutics Inc shares are lower during Wednesday's session, continuing a decline since Tuesday amid broader market concerns over persistent inflationary pressures.

2026. aug. 25. 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

2026. aug. 24. 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

2026. aug. 21. 19:56 UTC

Allogene Therapeutics Inc. shares are lower today, fluctuating within a routine range but remaining above their 20-day moving average.

2026. aug. 20. 22:16 UTC

Allogene Therapeutics Inc. shares are higher in after-market hours, despite earlier declines, amid rising U.S. Treasury yields and broader market pressure.

2026. aug. 19. 23:01 UTC

Allogene Therapeutics Inc. shares are lower in after-market hours, continuing a decline that began at the start of the session.

2026. aug. 18. 19:51 UTC

Correlated Moves

Allogene Therapeutics Inc. shares are trading lower amid broader market declines and rising Treasury yields, reflecting ongoing pressure in the biotechnology sector.

2026. aug. 17. 19:16 UTC

Correlated Moves
News

Allogene Therapeutics Inc shares rise following Citizens' Market Outperform rating and $6 price target. The broader Biotechnology sector also shows significant gains.

2026. aug. 14. 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. The stock remains above its 20-day moving average.

2026. aug. 13. 19:26 UTC

News

Allogene Therapeutics reported a net loss of $42.7 million, better than expectations, as shares trade lower amid concerns over a potential $500 million offering.

2026. aug. 12. 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

2026. aug. 11. 23:26 UTC

Allogene Therapeutics shares advanced during after-market hours, trading within a narrow range and remaining well above the 20-day moving average.

2026. aug. 10. 19:16 UTC

Allogene Therapeutics is trading higher, maintaining upward momentum despite a decline in U.S. stock futures following a labor market report.

2026. aug. 7. 19:16 UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

2026. aug. 6. 19:46 UTC

Correlated Moves

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

2026. aug. 5. 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

2026. aug. 3. 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

2026. júl. 30. 20:04 UTC

Correlated Moves
Event

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

2026. júl. 29. 23:51 UTC

Event
Correlated Moves

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

2026. júl. 28. 20:02 UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

2026. júl. 27. 18:07 UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

2026. júl. 24. 19:46 UTC

Correlated Moves

Allogene Therapeutics Inc is lower today amid broader market declines, with the Russell 2000 Index down and oil price volatility impacting the biotechnology sector.

Társak összehasonlítása

Árváltozás

Allogene Therapeutics Inc Előrejelzés

Célár

By TipRanks

506.51% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 10.25 USD  506.51%

Magas 14 USD

Alacsony 8 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Allogene Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

7 ratings

6

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

134 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat